KR20230088833A - T-세포 수용체 식별을 위한 조성물 및 방법 - Google Patents

T-세포 수용체 식별을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230088833A
KR20230088833A KR1020237017389A KR20237017389A KR20230088833A KR 20230088833 A KR20230088833 A KR 20230088833A KR 1020237017389 A KR1020237017389 A KR 1020237017389A KR 20237017389 A KR20237017389 A KR 20237017389A KR 20230088833 A KR20230088833 A KR 20230088833A
Authority
KR
South Korea
Prior art keywords
cells
mhc
tcr
cancer cell
hla
Prior art date
Application number
KR1020237017389A
Other languages
English (en)
Korean (ko)
Inventor
시 첸
Original Assignee
루트패스 제노믹스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루트패스 제노믹스, 인크. filed Critical 루트패스 제노믹스, 인크.
Publication of KR20230088833A publication Critical patent/KR20230088833A/ko

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114T cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539MHC-molecules, e.g. HLA-molecules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237017389A 2020-10-23 2021-10-22 T-세포 수용체 식별을 위한 조성물 및 방법 KR20230088833A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063104624P 2020-10-23 2020-10-23
US63/104,624 2020-10-23
US202063128274P 2020-12-21 2020-12-21
US63/128,274 2020-12-21
PCT/US2021/056208 WO2022087380A1 (en) 2020-10-23 2021-10-22 Compositions and methods for t-cell receptor identification

Publications (1)

Publication Number Publication Date
KR20230088833A true KR20230088833A (ko) 2023-06-20

Family

ID=81290091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017389A KR20230088833A (ko) 2020-10-23 2021-10-22 T-세포 수용체 식별을 위한 조성물 및 방법

Country Status (7)

Country Link
US (1) US20240118285A1 (de)
EP (1) EP4232080A1 (de)
JP (1) JP2023546950A (de)
KR (1) KR20230088833A (de)
AU (1) AU2021366741A1 (de)
CA (1) CA3194664A1 (de)
WO (1) WO2022087380A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299734A1 (de) * 2022-07-01 2024-01-03 ETH Zurich Zellinie zum auffinden von tcr-antigenen und verwendungen davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014223243B2 (en) 2013-03-01 2019-10-17 Regents Of The University Of Minnesota Talen-based gene correction
EP3368691A4 (de) * 2015-10-27 2019-04-03 Arizona Board of Regents on behalf of Arizona State University Hochdurchsatzidentifizierung von antigenen und epitopen zur t-zellerkennung
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
SG11202108613RA (en) * 2019-02-12 2021-09-29 Pact Pharma Inc Compositions and methods for identification of antigen specific t cells
JP2022524328A (ja) * 2019-03-06 2022-05-02 グリットストーン バイオ インコーポレイテッド Mhcクラスiiモデルによる新生抗原の特定

Also Published As

Publication number Publication date
CA3194664A1 (en) 2022-04-28
EP4232080A1 (de) 2023-08-30
AU2021366741A9 (en) 2024-05-23
WO2022087380A1 (en) 2022-04-28
AU2021366741A1 (en) 2023-05-11
US20240118285A1 (en) 2024-04-11
JP2023546950A (ja) 2023-11-08

Similar Documents

Publication Publication Date Title
US11946054B2 (en) Modulating expression of polypeptides via new gene switch expression systems
CN110191898A (zh) Cd33特异性嵌合抗原受体
EP3441461A1 (de) Cd1d-restringierte nkt-zellen als plattform für gebrauchsfertige krebsimmuntherapie
JP2020527937A (ja) 新規の細胞タグの発現
CN109937364A (zh) Mhc-e限制性表位、结合分子以及相关方法和用途
JP2017535261A (ja) Cart細胞における遺伝子発現の改変およびその使用
CN108473957A (zh) 改善嵌合抗原受体表达细胞的功效和扩增的方法
CN109072194A (zh) 免疫细胞组合物及其使用方法
CN113454117A (zh) Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
CN108779161A (zh) 重定向t细胞以治疗hiv感染的方法
JP2015524255A (ja) 二重特異性抗体を共導入することによってcart細胞の活性を強化する方法
JP2021515598A (ja) 融合タンパク質を用いたtcrリプログラミングのための組成物及び方法
CN104159909A (zh) 产生用于癌症治疗的t细胞持续性群体的组合物和方法
JP2020530277A (ja) 反復投与のための細胞免疫療法
US20220389406A1 (en) Compositions and methods for t-cell receptor identification
US20220062394A1 (en) Methods for identifying neoantigens
CA3162272A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
JP2023182711A (ja) 免疫療法のためのt細胞におけるcblbのcrispr-cas9編集のための方法、組成物および構成要素
KR20230024283A (ko) 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
CN114616323A (zh) 包含nef的t细胞及其产生方法
US20240118285A1 (en) Compositions and methods for t-cell receptor identification
CN116710473A (zh) 用于t细胞受体鉴定的组合物和方法
Ulaganathan et al. A strategy for uncovering germline variants altering anti-tumor CD8 T cell response
CN115516086A (zh) 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法
US20240360236A1 (en) Methods for targeted immunotherapy of acute myeloid leukemia (aml)